FDA Updates Labeling For RECLAST
RECLAST (active ingredient zoledronic acid) is a prescription medication manufactured by Novartis Pharmaceuticals Corporation for the treatment and prevention of postmenopausal osteoporosis. On September 2, 2011, the U.S. Food and Drug Administration (FDA) issued a labeling update for Reclast to b[...]